Chanelle Pharma
Chanelle Pharma is Ireland's largest indigenous generic pharmaceutical manufacturer, developing, registering, manufacturing, and out-licensing human and veterinary generic medicines to multinational pharmaceutical companies across 96 countries, with over 4,500 product licenses and 700+ employees.
- Company typePrivate
- Founded1985
- HeadquartersDublin, Ireland
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Chanelle Pharma does
Chanelle Pharma is Ireland's largest indigenous generic pharmaceutical manufacturer of both medical and veterinary products, founded in 1985 by veterinary surgeon Michael Burke and headquartered on an 18-acre campus in Loughrea, Co. Galway. The company develops, registers, manufactures, and out-licenses generic human and animal health pharmaceutical products, holding over 4,500 product licenses worldwide — including 3,000+ animal health licenses (described as the largest number of registered veterinary licenses of any company in the EU) and 1,200+ human health licenses. Operations span three manufacturing facilities in Ireland plus an R&D laboratory in Jordan (established 2008), with sales and marketing offices in the UK and Portugal, serving customers in approximately 96 countries across the EU, Canada, Asia, Australia, and the Middle East.
The company's core technology stack centers on integrated generic pharmaceutical development capabilities — product synthesis, formulation development, process validation, stability studies, bioequivalence studies, and regulatory dossier preparation — executed by 70+ scientists across five R&D laboratories. Manufacturing capabilities span tablets, capsules, organic liquids, powders and granules, coatings, and aqueous liquids, with specialization in anthelmintics, antibiotics, sedatives, NSAIDs, cardiovascular drugs, ectoparasiticides, and anti-epileptic drugs. In March 2026, Chanelle announced a strategic partnership with SAP to implement SAP S/4HANA Cloud (private edition) and SAP Business AI, targeting a late-2026 go-live for digital transformation of CDMO operations.
The business model is B2B sales-led, combining direct enterprise sales to major and indigenous generic pharmaceutical companies, out-licensing of dossiers to leading human generic and animal health multinationals (the company supplies 10 of the top 12 multinational animal health companies), contract development and manufacturing organization (CDMO) services, and a distributor/agent channel for Chanelle-branded veterinary products outside the EU. Animal Health was ranked 14th in Europe and 38th globally by S&P Global for fiscal 2023. Following the February 2024 acquisition by European private equity firm Exponent, the company installed a new senior leadership team (Angelo Gatto as first non-family CEO), expanded its Board of Directors with global animal health and manufacturing executives, restructured into two dedicated Animal Health and Human Pharma divisions, and is pursuing headcount growth (from approximately 550 to over 700 employees) supported by a domestic recruitment partnership with ICE Group.
Chanelle Pharma firmographics
Firmographics- Name
- Chanelle Pharma
- Legal name
- Chanelle Pharma Unlimited
- Website
- https://chanellepharma.com
- Company type
- Private
- Founded year
- 1985
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Chanelle Pharma is Ireland's largest indigenous generic pharmaceutical manufacturer, developing, registering, manufacturing, and out-licensing human and veterinary generic medicines to multinational pharmaceutical companies across 96 countries, with over 4,500 product licenses and 700+ employees.
- Ownership category
- akta.pro rank
Chanelle Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Chanelle Pharma is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices4 records
Markets served
Chanelle Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Generic Pharmaceutical Products: Development, registration, manufacturing and out-licensing of generic human pharmaceutical products. Products commercialised under labels of leading pharmaceutical companies worldwide.
- Veterinary Pharmaceutical Products: Development, registration, manufacturing and out-licensing of generic veterinary pharmaceutical products with diverse portfolio of large and small animal products supplying global market.
- Dossier and Finished Product Sales: Sale of generic and OTC dossiers and finished products to major and indigenous generic pharmaceutical companies.
- Contract Manufacturing Services: Contract development and manufacturing services for pharmaceutical companies with world-class manufacturing environment and ample capacity.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Chanelle Pharma product offering
Product offeringCore offering
Chanelle Pharma is Ireland's largest indigenous generic pharmaceutical manufacturer, developing, registering, and producing generic human medicines and a broad range of veterinary medicines for both companion and production animals. The company also offers integrated contract development and manufacturing services (CDMO) to other pharmaceutical companies, leveraging its in-house R&D labs and multi-format production facilities across Ireland, the UK, Portugal, and Jordan.
Product overview
Chanelle Pharma operates as a fully integrated pharmaceutical company offering both human and animal health generic products and contract manufacturing services. The human health division provides generic pharmaceuticals across therapeutic areas including CNS, Cox-2 Inhibitors, Antihistamines, Cardio/anti-hypertensive, Dermatology, Diabetes, and Osteoporosis. The animal health division offers an extensive portfolio of veterinary products including anthelmintics (Albex®, Animec®, Tribex®, Moxodex®, Bovex®), anaesthetics and sedatives (Bupaq®, Butador®, Chanazine®), NSAIDs (Canidryl®, Rheumocam®), antibiotics (Clinacin®, Fenoflox®, Milbotyl®), antiparasiticides (Fipnil®, Fleaway®, Prazitel®), and nutritional supplements (Chanatol®, Thrive Extra®). Beyond product sales, Chanelle Pharma provides comprehensive contract development and manufacturing organization (CDMO) services including R&D, formulation development, process validation, stability studies, bioequivalence studies, regulatory affairs support, and product packaging. The company serves B2B customers, distributors, and wholesale markets across approximately 90-100 countries worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- Albex: Anthelmintic product brand for cattle and sheep
- Moxodex
- Tribex
- Animec
- Bovex
- Rheumocam
- Canidryl
- Chanatol
- Fipnil
Products and services
- Human Health Generic Pharmaceuticals Portfolio of generic human pharmaceutical products developed and manufactured by Chanelle for distribution to multinational pharmaceutical companies and global procurement customers. Includes finished dosage forms across multiple therapeutic categories.
- Animal Health Veterinary Product Portfolio Broad branded veterinary medicine portfolio covering both companion (small) and production (large) animals, including brands such as Albex, Animec, Flimabo, Biodectin, Ectoline, Zerotal, Iver, Fenoflox, Closamectin, and Cydectin. Sold to animal health companies, distributors, and veterinary wholesalers worldwide.
- Contract Development and Manufacturing Services (CDMO) Integrated contract development and manufacturing services for human and animal health pharma clients, drawing on Chanelle's 70+ scientist R&D team and multi-format manufacturing capabilities (tablets, capsules, liquids, creams, ointments, sterile and non-sterile liquids, powders, granules, injectable vials).
Quantifiable outcome
- Over 4,500 licenses registered in countries worldwide
- +2 more outcomes
Companies that use Chanelle Pharma
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles2 records
Chanelle Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Chanelle Pharma partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship, core and minor.
- Galway Racecourseflagship41-year sponsorship partnership for Leading Trainer Award and Best Turned Out Series at Galway Races Summer Festival. One of the longest-running sponsorships in Irish racing.
- SAPcoreStrategic partnership to implement SAP S/4HANA Cloud (private edition) and SAP Business AI. Major investment in digital transformation for operational excellence with targeted go-live of late 2026.
- TenthpincorePartner for SAP implementation using sophisticated SAP Signavio processes optimized for Contract Development and Manufacturing Organisations (CDMOs).
- KaarTechcoreJoint implementation partner for SAP S/4HANA Cloud transformation project.
- ICE GroupminorDomestic recruitment partnership for Irish workforce expansion. ICE Group currently employs more than 700 people in Ireland.
Scale indicators13 records
Recent moves10 records
Expansion highlights6 records
Chanelle Pharma competitors and assessment
Company assessmentBroad incumbents
- Perrigo Company: Large global generic pharmaceutical manufacturer with a strong OTC and prescription generics franchise plus an animal health presence. Comparable as a broad incumbent in generic human and consumer health manufacturing where Chanelle's generic dossier/finished dose business competes.
Direct peers
- Vetoquinol: Independent French animal health pharmaceutical group offering generic and branded veterinary medicines across companion animal and livestock. Direct peer given its integrated R&D, manufacturing and global commercial model in animal health generics.
- Huvepharma: Bulgarian-headquartered global animal health and nutrition company with vertically integrated manufacturing of veterinary pharmaceuticals, vaccines and feed additives. Comparable given its generic-leaning animal health portfolio and global export model similar to Chanelle's.
- Ceva Santé Animale: Global veterinary pharmaceutical company headquartered in France, focused on companion animal, poultry, swine and ruminant pharmaceuticals and vaccines. Comparable to Chanelle in integrated development, manufacturing and worldwide distribution of veterinary generics and branded products.
- Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company focused on companion animal endocrinology, NSAIDs, antibiotics and dermatology. Highly comparable in veterinary pharmaceutical development, regulatory expertise and global distribution to vets and animal health distributors.
- Aenova Group: One of Europe's largest contract development and manufacturing organizations (CDMOs) for human pharmaceuticals, producing solid, semi-solid and liquid dosage forms. Closely comparable to Chanelle's CDMO offering (and a previous employer of Chanelle's CEO), serving major pharma companies with formulation, manufacturing and regulatory services.
- Norbrook Laboratories: UK/Ireland-headquartered generic veterinary pharmaceutical manufacturer with a globally distributed animal health portfolio of anti-infectives, anti-inflammatories and parasiticides. Direct comparable to Chanelle given similar geographic origin, generic vet focus, and CDMO-style offerings for global animal health companies.
- Adragos Pharma: European CDMO focused on solid oral dosage forms with sites in Germany, France and elsewhere. Highly comparable to Chanelle's contract manufacturing arm and to the CDMO capabilities being built out under Exponent's ownership.
Emerging players
- Alivira Animal Health: India-based animal health pharmaceutical company with a global generics portfolio across livestock and companion animals. Comparable as a low-cost emerging competitor in the same veterinary generic categories (anthelmintics, antibiotics, NSAIDs) where Chanelle operates.
- Putney Inc. US-based generic veterinary pharmaceutical company that was acquired for $200 million and whose founder now sits on Chanelle's board. Direct comparable in the US generic vet pharma space and a useful benchmark for what a focused generic animal health platform can be valued at on exit.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Chanelle Pharma social profiles
Digital presenceChanelle Pharma compliance and trust
Trust signalCompliance5 records
Chanelle Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chanelle Pharma leadership team
Management profileNumber of profiles
Profiles35 records
Chanelle Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Chanelle Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chanelle Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chanelle Pharma
What does Chanelle Pharma do?
Chanelle Pharma is Ireland's largest indigenous generic pharmaceutical manufacturer, developing, registering, and producing generic human medicines and a broad range of veterinary medicines for both companion and production animals. The company also offers integrated contract development and manufacturing services (CDMO) to other pharmaceutical companies, leveraging its in-house R&D labs and multi-format production facilities across Ireland, the UK, Portugal, and Jordan.
Is Chanelle Pharma a public or private company?
Chanelle Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was Chanelle Pharma founded?
Chanelle Pharma was founded in 1985. It employs 501 to 1,000 people.
Where is Chanelle Pharma based?
Chanelle Pharma is headquartered in Dublin, Ireland, in the Europe region.
How does Chanelle Pharma make money?
Four revenue lines are on record. Generic Pharmaceutical Products are the primary driver. The others are veterinary Pharmaceutical Products, dossier and Finished Product Sales and contract Manufacturing Services.
Who are Chanelle Pharma's main competitors?
Perrigo Company is listed as a broad incumbent. Direct peers are Vetoquinol, Huvepharma, Ceva Santé Animale, Dechra Pharmaceuticals, Aenova Group, Norbrook Laboratories and Adragos Pharma. Emerging players are Alivira Animal Health and Putney Inc..
Does Chanelle Pharma have an API?
No public API is recorded for Chanelle Pharma.
What industry is Chanelle Pharma in?
Chanelle Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.